All In Biotech

Drug Trial Radar · NCT05561634

Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

Evaluation of Radiotherapy After Complete Response to Sonic Hedgehog Pathway Inhibitors in Patients With Locally Advanced Basal Cell Carcinoma: a Prospective Multicenter Study

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Jun 20, 2023

Primary completion

Jun 20, 2029

Study completion Jun 20, 2029

Sponsor

Lead sponsor
University Hospital, LilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sun Pharmaceutical Industries Limited
First posted
Sep 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy. In these particular situations, surgery and radiotherapy are sometimes not appropriate, and Sonic Hedgehog inhibitors (SHHi) (Vismodegib and Sonidegib) can be proposed. SHHi are effective treatments in laBCC but most CR patients discontinue treatment because of tolerability. Approximately 65% of the population experience a relapse after discontinuation. A few cases of patients treated concomitantly by radiotherapy and vismodegib have been reported in the literature, suggesting that combining vismodegib and concomitant radiotherapy results in an improved overall response compared to a single modality treatment. There is no study evaluating a "consolidation radiotherapy" after complete response to SHHi. We carry out a prospective multicenter study in order to evaluate consolidation radiotherapy in patients with laBCC after achieving complete response with SHHi, with the hypothesis of reducing recurrence after discontinuation of SHHi.

Conditions

  • Basal Cell Carcinoma
  • Radiotherapy; Complications

Interventions

  • RadiotherapyRadiation

    Irradiation of the tumoral bed.

  • ObservationOther

    Patients will be followed up in consultation every 3 months.

  • VismodegibDrug

    Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of a local relapse at 2 years in both groups.Time frame: At 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU Lille

    Lille, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.